Compare IDEXX Laboratories, Inc. (IDXX) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs VICI Properties Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while VICI Properties Inc trades at $26.07 (market cap $28.61B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and VICI Properties Inc pays a 6.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | VICI | |
|---|---|---|
Market Cap | $46.22B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $33.78 |
52-Week Low | $526.44 | $25.94 |
Enterprise Value | $47.12B | $46.16B |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
VICI Properties trades at $26.07, down slightly by 0.02% on the day. The stock shows a bearish technical signal with moving averages indicating selling pressure, while fundamentals remain solid with a P/E of 10.07 and strong profitability margins. Recent Q2 2026 earnings missed EPS estimates but revenue beat, and the company raised its full-year AFFO guidance. A dividend of $0.45 per share was recently declared, supporting income appeal.
The outlook is mixed; analyst consensus is strongly bullish with a $29.83 price target, but near-term volatility exists due to the Caesars buyout overhang. The 6.6% dividend yield and balance sheet strength provide downside cushion, though high debt and interest expenses pose risks. Upside depends on execution of growth initiatives and stable cash flows from its real estate portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
